Tedros Urges Pfizer to Make Oral COVID Antiviral More Affordable |

Tedros Adhanom Ghebreyesus Appeal Confirmed coronavirus cases jumped almost 30 percent in the last two weekswith an increase in infections in four of the six regions of the world.

Agreement conditions

“Our organizations are still trying to negotiate appropriate terms with Pfizer for low- and middle-income countries,” he told reporters at his regular weekly briefing in Geneva.

It delays access and some countries may choose to wait for the universal version of the antiviral drug, which will probably only be available in early 2023, and that will cost lives. I urge Pfizer to work closely with health authorities and countries to ensure that a new oral antiviral drug is quickly and efficiently available.”

The UN Health Agency is working with the Global Fund and the UN Children’s Fund, UNICEFto help countries get antivirals when they become available.

These included distributions of molnupiravir, which were received by 20 countries, and nirmatrelvir-ritonavir or paxlovid, in which 43 countries expressed interest in receiving.

Variants of “drive waves” of infection

Overall, he said, in Europe and the Americas, the BA.4 and BA.5 sub-options were “driving waves” of new infections, while in some countries, including India, ” a new subline BA2.75 was also discovered, which we are following.“.

Four out of six WHO Sub-regions have seen an increase in cases over the past week, and compounding the problem, in addition to access to new treatments, is due to reduced testing in many countries and the simple fact that the vaccine defense is weakening.

Each wave of the virus, even if the number of hospitalizations and deaths is decreasing, leaves more people with long-term or post-COVID conditionsTedros warned, placing additional burdens on patients, loved ones, as well as “health systems, the economy at large and society at large.”

He said the research and development of “the next generation of vaccines, tests and treatments” needs to be accelerated, and the WHO is working with scientists around the world to make that happen.

© UNICEF/Dhiraj Singh

An employee works on a COVID-19 vaccine production line in India.

The “scale and spread” of monkeypox regarding

On the monkeypoxTedros said he continued to be “concerned about the scale and spread of the virus“.

Now were over 6,000 cases reported in 58 countriesTedros said, noting that it is “highly likely” that a significant number of cases have not been identified due to limited testing.

The epicenter of the outbreak is currently Europe, which accounts for more than 80 percent of cases worldwide.

In Africa, cases are emerging in previously unaffected countries, and a record number of cases have been confirmed in places where monkeypox previously.

Vaccine development

The WHO chief said the agency is working with countries and vaccine manufacturers to coordinate the exchange of vaccines, “which are currently scarce and should be accessible to people most at risk“.

WHO also works closely with civil society and the LGBTIQ+ community, especially in break the stigma around the virus and disseminate accurate and reliable information so that people can protect themselves, he added.

“I want especially praise those who share videos online through social media channels talking about their symptoms and experiences with monkeypox..

This is a positive way to break the stigma of a virus that can hit anyone.”

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button